drugset / Trial / NCT01023945

A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus

NCT01023945

Phase 1 Completed 30 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to evaluate the pharmacodynamic profile (blood glucose and urinary glucose excursion) of ASP1941 in patients with type 2 diabetes mellitus. Safety, tolerability and pharmacokinetics are also evaluated.

Timeline

Start
2009-11-07
Primary completion
2010-03-26
Completion
2010-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject ipragliflozin Small molecule Oral